These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36825662)

  • 1. Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD.
    Mesrouze Y; Gubler H; Villard F; Boesch R; Ottl J; Kallen J; Reid PC; Scheufler C; Marzinzik AL; Chène P
    ACS Chem Biol; 2023 Mar; 18(3):643-651. PubMed ID: 36825662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based derivation and optimization of YAP-like coactivator-derived peptides to selectively target TEAD family transcription factors by hydrocarbon stapling and cyclization.
    He B; Wu T; He P; Lv F; Liu H
    Chem Biol Drug Des; 2021 Jun; 97(6):1129-1136. PubMed ID: 33283479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Early Association between the α-Helix of the TEAD Binding Domain of YAP and TEAD Drives the Formation of the YAP:TEAD Complex.
    Bokhovchuk F; Mesrouze Y; Meyerhofer M; Zimmermann C; Fontana P; Erdmann D; Jemth P; Chène P
    Biochemistry; 2020 May; 59(19):1804-1812. PubMed ID: 32329346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design and chemical modification of TEAD coactivator peptides to target hippo signaling pathway against gastrointestinal cancers.
    Gao S; Wang Y; Ji L
    J Recept Signal Transduct Res; 2021 Aug; 41(4):408-415. PubMed ID: 32912021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
    Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
    Elife; 2017 Apr; 6():. PubMed ID: 28430104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
    Zhou W; Li Y; Song J; Li C
    Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery Challenge.
    Chène P
    ChemMedChem; 2024 Jun; ():e202400361. PubMed ID: 38863297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
    Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
    Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of TEAD transcription factors in cancer.
    Pobbati AV; Kumar R; Rubin BP; Hong W
    Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
    Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
    Elife; 2022 Nov; 11():. PubMed ID: 36398861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal β-strand in YAP is critical for stronger binding to scalloped relative to TEAD transcription factor.
    Bokhovchuk F; Mesrouze Y; Meyerhofer M; Fontana P; Zimmermann C; Villard F; Erdmann D; Kallen J; Scheufler C; Velez-Vega C; Chène P
    Protein Sci; 2023 Jan; 32(1):e4545. PubMed ID: 36522189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1102-1120. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.
    Furet P; Salem B; Mesrouze Y; Schmelzle T; Lewis I; Kallen J; Chène P
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2316-2319. PubMed ID: 31235263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
    Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
    Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.